world anti-doping agency bpc-157 prohibited list 2025 WADA publishes 2026 The 2025 WADA List of

Purity was independently confirmed in-house by HPLC prior to use

Sikiric's lab in Croatia) No independent replication No competing research Raises red flags about bias Human data: ONE small retrospective study (not a randomized trial) No large-scale clinical trials No safety studies Unknown dosing Unknown side effects Recent systematic review (2024): Published in orthopaedic literature, concluded: "BPC-157 has potential based on preclinical data, but there is a concerning lack of published clinical trial data because studies appear to have been cancelled or stopped without publication." Reported Side Effects (From Online Users): Anonymous reports include: Injection site pain and swelling Joint pain Anxiety and panic attacks Heart palpitations Insomnia or drowsiness Fatigue and weakness Loss of appetite Depression and anhedonia (inability to feel pleasure) Note: These are anecdotal, not from clinical trials

The enhanced cell migration from TB-500 pairs with the increased fibroblast function from BPC-157, creating conditions favorable for rapid tissue repair

CJC-1295 (No DAC) (Mod GRF 1-29) functions as a short-acting GHRH analog, while Ipamorelin acts as a selective ghrelin mimetic and GHS-R agonist

CV outcomes data (SELECT) These compounds are not interchangeable